Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 29, 2019. The report details a strategic development by ViiV Healthcare, a global specialist HIV company majority-owned by GSK (with Pfizer Inc. and Shionogi Limited as shareholders). The filing announces the submission of a New Drug Application (NDA) to the US FDA for a novel HIV treatment regimen.
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This document is a current report focused on a regulatory milestone rather than a financial statement.
Material Changes and Developments
- Regulatory Submission: ViiV Healthcare submitted an NDA to the US FDA for a monthly, injectable, two-drug regimen of cabotegravir and rilpivirine for the treatment of HIV-1 in adults.
- Product Innovation: If approved, this would be the first-ever long-acting, injectable treatment regimen for adults living with HIV, reducing treatment frequency from 365 daily doses to 12 monthly injections per year.
- Clinical Evidence: The submission is based on the ATLAS and FLAIR pivotal Phase III studies involving over 1,100 patients across 16 countries. Results demonstrated the regimen was as effective as standard daily oral therapy in maintaining viral suppression over 48 weeks.
- Patient Preference: More than 85% of study participants preferred the monthly injectable regimen over their prior daily oral therapy.
- Additional Submission: A second NDA was submitted for an oral tablet formulation of cabotegravir to serve as a lead-in therapy.
Outlook, Risks, and Management Commentary
Management Commentary: Deborah Waterhouse, CEO of ViiV Healthcare, stated the regimen offers a novel option with similar safety and efficacy to standard care but with improved convenience. John C. Pottage, Jr., M.D., Chief Scientific and Medical Officer, emphasized that the data supports the efficacy and safety of the two-drug regimen.
Future Outlook: ViiV Healthcare and Janssen plan to submit regulatory applications to the European Medicines Agency, Health Canada, and other global agencies in the coming months.
Risks and Contingencies:
- Regulatory Approval: The filing is contingent upon FDA approval; the drugs are currently investigational and not approved anywhere in the world.
- Safety Profile: The filing includes extensive safety information for rilpivirine (EDURANT), noting risks of severe skin rash, allergic reactions, liver enzyme changes, depression, and immune reconstitution syndrome.
- Forward-Looking Statements: GSK cautions that actual results may differ materially from projections due to risks described in their 2018 Annual Report on Form 20-F.
Investor Verification Checklist
- Verify the FDA's decision timeline and final approval status for the cabotegravir and rilpivirine injectable regimen.
- Monitor the submission and approval status of regulatory applications in the EU, Canada, and other global markets.
- Review the commercial launch strategy and potential market share impact against existing daily oral HIV therapies.
- Assess the long-term safety data and post-marketing surveillance requirements for the injectable formulation.
- Confirm the financial impact of this product on ViiV Healthcare's and GSK's future revenue streams once approved.